MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...